Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

84.08CHF
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
CHF84.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,390,129
52-wk High
CHF88.30
52-wk Low
CHF71.84

Select another date:

Tue, Oct 16 2018

BRIEF-Sandoz Launches Biosimilar Version Of Abbvie's Humira In UK

* NOVARTIS UNIT SANDOZ LAUNCHES HYRIMOZ, ITS BIOSIMILAR VERSION OF ABBVIE'S HUMIRA, IN UK AS OF OCT 16; OTHER EUROPEAN MARKETS TO FOLLOW -SPOKESMAN Further company coverage: (Reporting by UK bureau)

BRIEF-Novartis says 5-year data reinforce cosentyx leadership in spondyloarthritis

* NOVARTIS 5-YEAR DATA IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS REINFORCES COSENTYX® LEADERSHIP IN SPONDYLOARTHRITIS Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Abbvie settles Humira patent disputes with Novartis unit

Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.

Abbvie settles Humira patent disputes with Novartis unit

Oct 11 Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.

BRIEF-Novartis Announces Data From Trial To Show Superior Efficacy Of Gilenya Over Copaxone In Patients With Relapsing Remitting Multiple Sclerosis

* NOVARTIS ANNOUNCES NEW DATA FROM THE FIRST DIRECT HEAD-TO-HEAD TRIAL TO DEMONSTRATE SUPERIOR EFFICACY OF GILENYA® OVER COPAXONE® IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

BRIEF-Novartis seeks U.S., EU regulatory approval for MS drug Siponimod

* NOVARTIS ANNOUNCES FDA AND EMA FILING ACCEPTANCE OF SIPONIMOD, THE FIRST AND ONLY DRUG SHOWN TO MEANINGFULLY DELAY DISABILITY PROGRESSION IN TYPICAL SPMS PATIENTS

BRIEF-Novartis licenses three anti-infective programnes to Boston Pharmaceuticals

* NOVARTIS LICENSES THREE NOVEL ANTI-INFECTIVE PROGRAMS TO BOSTON PHARMACEUTICALS

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 (362,663 pounds) gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

UPDATE 1-Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country. Local regulations require that Novartis manufactures Kymriah in China if it wants to treat the country's patients with the drug.

Select another date: